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Fuenlabrada, Madrid, SpainAbstractSince 2009, the largest reported outbreak of leishmaniasis by Leishmania infantum in Europe was reported in Fuenlabrada, Spain. In our
hospital, 90 adults with localized leishmanial lymphadenopathy (LLL) or visceral leishmaniasis (VL) were treated during this outbreak; 72%
were men, and the mean age was 46.2 years (range 15–95 years). A total of 17 cases (19%) were LLL, an atypical form with isolated
lymphadenopathies without other symptoms. All LLL cases occurred in immunocompetent subjects, and only one subject (6%) was a
native of sub-Saharan Africa. Diagnosis was performed by ﬁne needle aspiration cytology of the lymphadenopathy. Serology was negative
in 38%. LLL outcomes at 6 months were benign, even with doses of liposomal amphotericin B that were often lower (10 mg/kg) than
those recommended for VL in Mediterranean areas. A total of 73 subjects (81%) presented with typical VL; 66% of this group were
immunocompetent, and 50% of those who were immunocompetent were descendants of natives of sub-Saharan Africa. The rK39 test
and polymerase chain reaction were the most useful tests for conﬁrmation of the diagnosis. An initial response to treatment was
observed in 99% of cases, and relapses occurred in 14% of cases. Leishmaniasis should be included in the differential diagnosis of isolated
lymphadenopathies in endemic areas. LLL could be considered a more benign entity, one different than VL, and less aggressive
management should be studied in future investigations.
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should be considered ﬁrst author.IntroductionLeishmaniasis is an infectious disease caused by the Leishmania
spp. parasite and is transmitted to humans by the bite of
phlebotome sandﬂies. It is an endemic disease in 98 countries,Clinical Microbiology and Infection © 2014 European Society of Cincluding those of the Mediterranean basin [1]. Visceral leish-
maniasis (VL) is the most serious clinical form of this disease;
symptoms include weight loss, intermittent fever and spleno-
megaly [2]. Without treatment, it can be fatal, in contrast to
cutaneous leishmaniasis (CL), which presents a less aggressive
course.
Lymphadenopathies are not common in VL, except in
Eastern Africa [3], but some forms of CL present lymphade-
nopathies near the cutaneous injury [4]. Nevertheless, in the
Mediterranean area, isolated cases of an infrequent form of
leishmaniasis involving isolated lymphadenopathies without fe-
ver or skin lesions have been described in a few case reports as
localized leishmanial lymphadenopathy (LLL) [5–9]. The clinicalClin Microbiol Infect 2015; 21: 269–273
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.10.017
270 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMImanagement of LLL is not well deﬁned because it is not a classic
form of VL or CL [5,8].
Leishmaniasis in Spain is endemic and is caused by Leishmania
infantum, which can cause VL or CL, and whose typical reservoir
is the dog. Since July 2009, an outbreak of leishmaniasis has been
developing south of Madrid, primarily in the city of Fuenlabrada;
byDecember 2012, this outbreak had already affectedmore than
400 people (making it the largest reported community outbreak
in Europe), consisting of one-third VL and two-thirds CL. The
epidemiologic features and control measures of this outbreak
have been reported by Arce et al. [10]. As peculiarities of the
outbreak, a genotype of L. infantumwas found (genotype L-920 or
L-962, ITS LOMBARDI) [11], and a new reservoir, the hare, was
identiﬁed [12]. Despite reaching a peak incidence in 2011, the
outbreak as of this writing in 2014 remains active.
Our aim was to describe this atypical presentation charac-
terized by lymphadenopathy and to highlight its differences
from the usual form of VL.Materials and methodsDesign
Using a prospective database of all adult patients with VL
treated at the Hospital Universitario de Fuenlabrada (HUF)
during the epidemic outbreak (1 June 1 2009 to 31 May 2013),
we retrospectively analysed the disease’s epidemiologic, clinical,
diagnostic and treatment characteristics. All of the patients
were followed for at least 6 months after treatment; the study
ended 1 February 2014.
Case deﬁnitions
Visceral leishmaniasis (VL). Typical symptoms or signs (prolonged
and intermittent fever, weight loss, pancytopenia or spleno-
megaly) with serologic or parasitologic conﬁrmation approved
by the World Health Organization (WHO) report [1].
Localized leishmanial lymphadenopathy (LLL). Lymphadenopathies
(>1 cm cervical or axillar, >2 cm inguinal) as the ﬁrst clinical
manifestation, with parasitologic conﬁrmation by stained smear,
culture or polymerase chain reaction (PCR) from lymph node
biopsy or aspirated material [5].
Initial response to treatment. Clinical improvement at the end of
treatment [1].
Relapse. Reappearance of clinical disease after response to initial
treatment [1].
Deﬁnitive response to treatment.. Absence of clinical disease at
least 6 months after completing treatment [1].Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectPatients
All patients older than 14 with case deﬁnition criteria treated at
the HUF were included in the study. Solid-organ transplant
recipients with VL were not included because these recipients
were referred to other centres.
Laboratory diagnostic methods
Antileishmanial antibodies were mainly assayed using an
immunochromatographic test based on the rK39 antigen (SD
Leishmania Ab; Standard Diagnostics) and using an enzyme-
linked immunosorbent assay (ELISA) for the detection of total
antibodies (leishmania ELISA IgG + IgM; Vircell Microbiologists).
In a few patients, antibodies were detected using indirect
immunoﬂuorescence (Leishmania Indirect Immunoﬂuorescence
Antibody Test; Vircell); titres of 1:80 were considered sig-
niﬁcant. Leishmanial cultures were created by inoculating the
tissue specimens or the buffy coat layer of peripheral blood
onto Novy-McNeal-Nicolle medium. All cultures were incu-
bated at room temperature (22°C to 25°C) and were examined
every other week for 6 weeks. Tissue samples were stained
with May-Grünwald-Giemsa or periodic acid–Schiff. DNA
extraction and ampliﬁcation of a portion of the 18S rDNA of
Leishmania spp. were performed as described elsewhere [13].
Data collection and statistical analysis
Epidemiologic, clinical, diagnostic and treatment characteristics
were collected in a speciﬁcally designed case report form.
All statistical analyses were conducted by SPSS software,
v11.5 (SPSS).
The qualitative variables are expressed as the percentages of
the total number of patients. The quantitative variables appear
as the mean and standard deviation or medians and interquartile
ranges (for skewed variables). The variables were compared
depending on the clinical form, VL vs. LLL. To compare the
qualitative variables, we used a chi-square test or Fisher’s test
when the number of cases was fewer than ﬁve. The quantitative
variables were evaluated for normal distribution according to
the Kolmogorov-Smirnov test. Normal quantitative variables
were compared by analysis of variance. Nonnormal quantitative
variables were compared using the nonparametric Kruskal-
Wallis test.ResultsIn total, 90 adults who fulﬁlled the case deﬁnitions were treated
at the hospital during this outbreak from 1 June 2009 through
31 May 2013; 65 (72%) were men, and the mean age of the
subjects was 46.2 years (standard deviation 16.2; range 15–95
years).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 269–273
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and 17 (19%) were LLL. The epidemiologic, clinical, laboratory,
diagnostic and outcome features of both groups are listed in
Table 1.
Localized leishmanial lymphadenopathy
LLL appeared as long evolution lymphadenopathies (median 60
days, interquartile range 75), and no patient presented either
fever or any other systemic symptom during the evolution.
Nine cases (53%) had more than one lymphadenopathy, with
two (12%) in different lymphadenopathy areas. The most
frequent location was the cervical area (11 cases, 65%),
including the laterocervical, submandibular and parotid chains.
Six patients (35%) presented with inguinal lymphadenopathies,
three presented with (18%) axillary lymphadenopathies, one
presented with supraclavicular lymphadenopathy and one pre-
sented with costal lymphadenopathy. Six patients (35%) pre-
sented with a cutaneous lesion suspicious of CL before the
appearance of the lymphadenopathy.
Diagnosis was performed in all LLL cases by ﬁne needle
aspiration cytology (FNAC) of the lymphadenopathy. The
pathologic ﬁnding was nonnecrotizing granulomatous lymph-
adenitis with Leishmania parasites in all cases, except for one
that did not exhibit granulomas. Serologic test results are
shown in Table 1.
One patient did not receive any treatment because of the
spontaneous resolution of the lymphadenopathy 6 months after
diagnosis. The rest were treated with liposomal amphotericin B
(LAB), but different doses were used depending on physician
decision. Four patients were treated with 10 mg/kg, ﬁve with
15 mg/kg, one with 18 mg/kg and six with 21 mg/kg of LAB.
One patient whose disease presented exclusively in the
cervical nodes at the ﬁrst visit developed new inguinalTABLE 1. Clinical features of subjects with VL and LLL
Clinical feature VL (n [ 73)
Male, n (%) 56 (77%)
Age (mean ± SD) 46.3 ± 16.7
Immigrant, n (%) 33 (45%)
Sub-Saharan native, n (%) 26 (36%)a
Immunocompetent, n (%) 48 (66%)a
Fever, n (%) 69 (95%)
Clinical splenomegaly, n (%) 27 (37%)
Radiologic splenomegalyb 64/68 (94%)
Anaemia (Hb < 12 mg/dL), n (%) 65 (89%)
Leukopenia (<4000/mm3), n (%) 64 (88%)
Thrombocytopenia (<150 000/mm3), n (%) 69 (95%)
C-reactive protein >2 mg/dLb 65/68 (96%)
Ferritin >1000 mg/dLb 43/56 (77%)
Erythrocyte sedimentation rate >30 mm/hb 25/27 (93%)
rk39 testb 32/48 (67%)
ELISA/IFAb 70/71 (99%)
Initial response to treatment 69/70 (99%)
Relapse 10/70 (14%)
VL, visceral leishmaniasis; LLL, leishmanial lymphadenopathy; Hb, haemoglobin; ELISA, enzym
aFor VL in immunocompetent subjects, 50% of cases occurred in descendants of sub-Sahara
bNumber of cases with positive result on diagnostic test/total number of cases with diagnos
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologylymphadenopathies by the end of treatment (21 mg/kg LAB) and
was considered an initial treatment failure. Leishmania was
conﬁrmed by FNAC of both lymphadenopathies, cervical and
inguinal. This patient was the only one with LLL who had clinical
and radiologic splenomegaly and had anaemia, leukopenia and
thrombocytopenia (Table 1). She was treated again with 40 mg/
kg of LAB, and her disease showed a deﬁnitive response. The
rest of the patients experienced an initial and deﬁnitive
response to treatment, and regardless of the dose used, all
exhibited deﬁnitive response to treatment at 6 months
(Table 1).
Typical VL
In total, 73 patients had typical manifestations of VL. Of these
patients, 48 were immunocompetent (66%) and 25 (34%) were
administered some potentially immunosuppressive drug or had
disease: nine (12%) had chronic human immunodeﬁciency virus
(HIV) infection, ten (14%) were receiving immunosuppressive
drugs (anti–tumour necrosis factor drugs, methotrexate and/or
steroids), three (4%) had hepatic cirrhosis and three (4%) had
active solid malignancies.
There were only four patients without fever (Table 1); three
were in patients with HIV, two were assessed for pancytopenia
and one was assessed for hypertransaminasemia. The only
immunocompetent patient without fever was diagnosed
because of thrombocytopenia.
Only one patient with typical VL had lymphadenopathies. He
was coinfected with HIV and leishmaniasis. FNAC showed
pathologic changes related to HIV but showed no evidence of
Leishmania.
Stained smear of bone marrow was positive for Leishmania in
44% cases and PCR of bone marrow in 91%. Serologic test
results are compared with LLL in Table 1.LLL (n [ 17) Total (n [ 90) p
9 (53%) 65 (72%) 0.049
45.5 ± 14.2 46.2 ± 16.2 0.858
2 (12%) 35 (39%) 0.012
1 (6%) 27 (30%) 0.014
17 (100%) 65 (72%) 0.002
0 (0%) 69 (77%) <0.001
1 (6%) 28 (31%) 0.013
1/7 (14%) 65/75 (87%) <0.001
1 (6%) 66 (73%) <0.001
1 (6%) 65 (72%) <0.001
1 (6%) 70 (78%) <0.001
1/14 (7%) 66/82 (81%) <0.001
0/8 (0%) 43/64 (67%) <0.001
1/4 (25%) 26/31 (84%) 0.008
3/6 (50%) 35/53 (66%) 0.352
8/13 (62%) 78/84 (93%) <0.001
15/16 (94%) 84/86 (98%) 0.354
0/16 (0%) 10/86 (12%) 0.099
e-linked immunosorbent assay; IFA, immunoﬂuorescent antibody.
n natives.
tic test performed (%).
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patients did not show up to receive treatment and were lost to
follow-up, and the other patient died from complications of
advanced cirrhosis before initiating therapy.
A total of 70 patients with VL received therapy with LAB. An
initial response to treatment was observed in 69 cases (99%),
and there were ten relapses (14%) during follow-up (Table 1).
All HIV patients were considered for receipt of monthly sec-
ondary prophylaxis. In total, ﬁve of the patients who experi-
enced relapse (50%) were natives of sub-Saharan Africa,
including two HIV patients who voluntarily discontinued sec-
ondary prophylaxis. After retreatment of the relapse, seven
patients were cured and three were not: one HIV patient with a
CD4 count of less than 100 cell/μL at the time the study closed
experienced four relapses, and two patients with severe co-
morbidity died before completing repeat treatment.DiscussionHere we report our clinical experience of the largest outbreak
of VL due to L. infantum in Europe to date. We diagnosed a
substantial number of cases of LLL, an atypical presentation that
has rarely been reported in the literature [5–9]. To our
knowledge, this is the ﬁrst series of cases of LLL caused by
L. infantum, and we compared it to VL during the outbreak.
LLL exclusively affected immunocompetent individuals,
whereas immunosuppressed patients were 34% of VL cases.
The immune factors that explain why L. infantum produces VL,
LLL or CL in immunocompetent individuals remain unknown. It
is remarkable the number of VL cases in immunocompetent
descendants of natives of sub-Saharan Africa (ratio 1:1),
whereas only one patient had LLL (ratio 1:16). In addition, in
this outbreak, very few CL cases were found in natives of sub-
Saharan Africa [10,14]. The reasons for this difference might be
due to external factors (habits, house conditions or location)
that suggested a major exposure of sub-Saharan patients to
Phlebotomus. However, the epidemiologic studies performed in
that zone have not found any exposure factor, such as contact
with dogs, the presence of vectors in their domestic or peri-
domestic environment or any of the classical environmental risk
factors [10]. Thus, the difference in susceptibility to VL among
natives of sub-Saharan Africa and natives of Spain could be
explained by genetic differences in the predisposition to this
disease, as others have suggested [15]. More studies should be
performed to prove this.
LLL presented an indolent evolution, without systemic
sequelae and without blood count and biochemical laboratory
test abnormalities. This suggests that patients were able to
control the infection. Dissemination to severalClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectlymphadenopathy areas was only conﬁrmed in one patient, and
this patient was the only one who had features of VL, i.e.
splenomegaly and pancytopenia. In contrast, fever, splenomeg-
aly and pancytopenia were present in more than 90% of the
typical VL cases, and as expected, this combination of ﬁndings
was the most frequent form of presentation [1].
We should include LLL in the differential diagnosis of any
isolated lymphadenopathy, at least in areas endemic for leish-
maniasis, such as Spain and the Mediterranean basin; diagnosis is
easy with FNAC [5–9]. Serology is not useful in CL because
most patients have negative results [1]. In our LLL cases, we
found a high proportion of false-negative results by serology
(50% for rK39 test, 40% for ELISA/immunoﬂuorescent antibody
(IFA) test; Table 1). However, for VL cases, rK39 antigen had a
100% predictive positive value and ELISA/IFA had 99% sensi-
tivity. These results in VL are similar to those reported in the
literature because the rK39 test is considered a more speciﬁc
test than ELISA/IFA [16].
WHO recommendations for L. infantum VL treatment in
immunocompetent individuals in the Mediterranean area include
LAB at a total dose of 18 to 21 mg/kg [17–19], but treatment for
LLL is not standardized, and no recommendations are provided
in the WHO report [1]. In previous case reports, LLL was sup-
posed to be treated like the visceral form, but treatment was
diverse: treated but drug not reported [9], antimonial therapy
[6], LAB but dose not reported [8], LAB 10mg/kg per day [7] and
LAB 30 mg/kg total dose [5]. We found that clinical character-
istics, diagnostic proﬁle and evolution of LLL seem to be closer to
CL than to typical VL, and we have documented spontaneous
clinical resolution of lymphadenopathies without treatment in
one patient. However, concerns about a change of immuno-
competence and parasite dissemination exist. Previous LLL cases
had been treated as VL [5,6,8,9]. In one patient, we found
dissemination to several lymphadenopathy locations and
splenomegaly, although we think this was a true case of VL
because of anemia and splenomegaly.
In our opinion, there are reasons to propose the systemic
treatment of this entity, but there are also reasons to support a
lower dose than that currently recommended for VL. A lower
dose of LAB (10 mg/kg) has been proved to not be inferior to
the conventional dose in VL due to Leishmania donovani [1,20];
LLL patients are immunocompetent, so their bodies can
partially control the infection; the number of parasites in the
total body is thus expected to be lower in LLL than in VL, and
lower toxicity is desirable. We found that 4 LLL patients
treated with LAB at a dose of 10 mg/kg had safe outcome at 6
months, and we suggest that in the absence of splenomegaly,
pancytopenia or elevation of phase reactants, it can be a
treatment option for LLL that must be investigated in the
future.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 269–273
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studies, which do not allow deﬁnitive conclusions concerning
diagnostic and treatment regimens to be made because of the
requirement for comparative clinical trials. This unexpected
outbreak did not allow us to design a randomized controlled
trial.
To summarize the principal lessons learned, we emphasize
that we should include leishmaniasis in the differential diagnosis
of isolated lymphadenopathies in immunocompetent subjects in
endemic areas. LLL usually had an indolent outcome different
from VL and could be treated with lower doses of LAB than
that recommended for VL in the Mediterranean area, although
further data are needed.Transparency declarationThis study received ﬁnancial support from the ‘Red de Inves-
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